Telehealth medical director: the role, the cost, and a compliant deal

The first search most founders run after deciding to launch an online clinic is some version of telehealth medical director cost, and the results mislead in a specific way. They present the medical director as the thing that makes a non-clinician's business allowed to practise medicine, and price it as a monthly line item. Neither is right. A medical director is a clinical-governance role inside a medical practice: the physician who owns the protocols, reviews the quality of the treatment and answers to the board for it. The role does not make a brand a practice, it does not supply the licence a practice needs, and in a white-label model the practice, and the role, already exist before the brand signs.

What a medical director does, and does not

The medical director is the physician responsible for the clinical operation of the practice. In a telehealth clinic the work is concrete and mostly written. The director approves the treatment protocols the providers follow and the titration schedules, inclusion and exclusion criteria and lab requirements inside them. The director reviews charts on a sampling schedule and follows up on the ones that fall outside protocol. The director sets the credentialing standard for providers, reviews adverse events and patient complaints, signs off on the standing orders the pharmacy and lab relationships rely on, responds to board inquiries, and updates the protocols when the evidence or the rules change.

What the director does not do is equally important to write down. The director does not, by virtue of the title, own the practice; ownership is a separate question governed by the corporate practice of medicine rules of each state. The director does not supervise nurse practitioners in the states that require physician collaboration unless the director separately holds that role under a collaboration agreement that meets that state's rules. The director does not see patients unless also engaged as a treating provider. And the director is not a licence for the management company: an MSO with a medical director and no physician-owned professional entity is still an unlicensed entity practising medicine in the states that enforce the doctrine. The guide on whether an operator needs a medical licence covers that question directly.

Medical director, collaborating physician and PC owner are three different jobs

Three physician roles appear in every telehealth structure and founders routinely expect one person and one contract to cover all of them. They can be held by one person, but they are different jobs with different legal sources, and the contracts and fees should separate them.

The medical director, described above, is a governance role created by the practice's own policies and, in some states, by facility or pharmacy rules that require a named responsible physician. The collaborating physician is a role created by state nurse-practice law. In states that do not grant nurse practitioners full practice authority, an NP may prescribe only under a written collaboration or supervision agreement with a physician, and that physician must meet state-specific conditions, often including licensure in the same state, chart-review ratios and limits on how many NPs one physician may cover. The number of states granting full practice authority changes with each legislative session and is best checked against the American Association of Nurse Practitioners' current map rather than a remembered figure. The PC owner is a role created by corporate law: the licensed physician who holds the shares of the professional entity in states that require physician ownership, and whose relationship with the management company is defined by the succession and stock-transfer agreements described in the friendly PC entry.

A physician can be all three. Many small clinics start that way. But the fee for each role should be set separately, because each one is measured against a different fair-market-value benchmark, and because a single blended payment is the thing a board reads as a payment for ownership rather than for work. The collaboration fee in particular is state-specific and may need to be paid to a different physician in each state where collaboration is required, which is why a national NP-staffed clinic ends up with several collaboration agreements alongside one medical director.

What the role costs

There is no public benchmark for medical director pay in consumer telehealth, and the figures that circulate come from the vendors that place physicians in the role. With that caveat stated, one telehealth staffing vendor quotes a range of $500 to $6,000 a month for a telehealth medical director, and a physician-staffing vendor quotes $400 to $2,500 a month for collaborating physicians, varying by state. Both are vendor-reported ranges, both are wide, and neither should be treated as a market rate. They are useful only for what drives the spread.

What moves the number is the volume of governance work rather than the volume of patients. A clinic with one protocol, one drug class and a few hundred charts a month needs a few hours of the director's time. A clinic with seven verticals, controlled substances, compounded medications and a multi-state provider bench needs a director who is licensed in the relevant states, comfortable with DEA and board correspondence, and available for incident review at short notice, and that physician commands a different fee. Specialty matters at the margins, and whether the director or the practice carries malpractice coverage for the governance role changes the fee. The fee should be higher, not lower, when the director will actually review charts, because a director who never reviews anything is worth nothing to the practice and is a liability to the operator.

The costs that do not appear in the vendor ranges are the ones that decide the deal: a written rationale for the fee, the director's malpractice endorsement, counsel's time drafting the agreement to fit every state in the footprint, and the recruitment cost when the first director leaves, which is the moment most small clinics discover that the protocols lived in that physician's head rather than in a document the practice owns.

Terms that get operators in trouble: percentage fees and volume bonuses

The medical director agreement is the most examined contract in the structure after the management services agreement. The fee should be a flat retainer, or a flat hourly rate against a documented estimate, for defined governance services, set at fair market value and revisited on a schedule. Every departure from that pattern creates a problem under at least one of three rules: the state's fee-splitting prohibition, the state's corporate practice doctrine, and, where any federal program is involved, the federal anti-kickback statute. The terms most often flagged:

• A fee set as a percentage of revenue or collections, which is fee splitting in most states and gives the payer a direct interest in prescribing volume.
• A bonus per prescription, per new patient or per consult completed, which is a payment for volume by another name.
• Equity in the management company granted to the director on terms tied to the practice's growth, which has the same effect one step removed.
• A fee that rises and falls with the number of patients under a protocol, with no corresponding change in the director's hours.
• Any payment for referring patients to a pharmacy, lab or other vendor the practice or the MSO has an interest in.
• A title with no work behind it: a director who has never seen the protocols, never reviewed a chart and never been consulted on an incident, which boards treat as evidence that the practice is run by someone else.
• A clause that gives the management company the power to overrule the director on a clinical matter, which converts the governance role into a formality and the structure into a shell.
• No written agreement at all, or one that does not describe the services, the hours or the basis for the fee.

The federal signal points the same way. In 2025 the HHS Office of Inspector General issued Advisory Opinion 25-03 approving a telehealth arrangement with multiple management services organizations, and the law-firm summaries of the opinion emphasize that the fees fit an anti-kickback safe harbor: fixed in advance, at fair market value, not tied to the volume or value of referrals. A cash-pay clinic that never bills a federal program is outside the federal statute, but state boards and state anti-kickback laws borrow the same tests, and an operator who can show that the medical director fee would pass the federal safe harbor is in a strong position before any state board.

A director who is paid more when more is prescribed is a director with a reason to prescribe, and every board rule on the subject exists to remove that reason.

Where the role sits in the MSO and friendly-PC structure

The medical director is engaged by the professional entity, never by the management company. The MSO pays the professional entity a management fee under the management services agreement; the professional entity pays the director. The director reports to the physician owner of the professional entity, and the management agreement reserves clinical governance, which is the director's whole job, to the professional entity in writing. The MSO can propose, can fund, can build the software the protocols run in, and can hire the non-clinical staff. It cannot direct the director.

This placement is what makes the role useful in a board review. When a board asks who set the prescribing criteria for a weight-loss program, the answer is a named physician inside the practice, with dated protocol revisions and a record of chart reviews. When the director and the physician owner are different people, the owner is the director's supervisor and the succession agreement covers the owner; when they are the same person, the practice needs a plan for the day that person leaves, because both roles vacate at once.

An operator inheriting a structure should check that the director's agreement is with the professional entity, that the management agreement gives the MSO no clinical veto, and that the protocols are documents the professional entity owns rather than files on the director's laptop.

When a brand needs its own versus the platform's

In a white-label model the answer to "do I need a medical director" is usually that the brand already has one. The professional entity that delivers treatment to the brand's patients has a medical director, protocols, a credentialing standard and a chart-review process, and the brand inherits all of them when it plugs in. A brand launching on a platform that runs its clinical operation through such an entity should ask to see the director's name, the protocol list and the review cadence, and should read the management agreement to confirm the governance is reserved to the professional entity. If those answers come back clearly, hiring a second director for the brand adds cost and a second opinion on every protocol without adding compliance.

A brand needs its own director in a few identifiable situations. When the brand owns its own professional entity and staffs its own providers, the director is the brand's to hire. When the brand's treatment area falls outside the platform's protocols, for instance a specialized hormone program or a treatment the platform's director has not approved, the brand may need a physician with that expertise engaged by the professional entity for that program. When investors or an acquirer want a named clinical lead in diligence, the role may be worth filling for that reason alone. And when the brand wants a physician as its public face, that is a spokesperson role, contracted separately at a marketing rate, and should not be confused with the governance role or paid as if it were one.

In Tessic Health's model the friendly professional entity set up as part of the client's structure carries the medical director role, the protocols and the chart-review process, and the client's providers, drawn from a network licensed in all fifty states, practise under them. The client does not recruit, contract or pay a director separately, and the structure is drafted for the client's ownership so that the governance travels with the client's entity rather than staying behind with the platform. Where a client's program needs a physician with particular expertise, that physician is engaged by the professional entity on a flat fee for the defined work.

Questions operators ask

Does a nurse practitioner-staffed clinic need a medical director at all? In full-practice-authority states the NPs can prescribe without physician involvement, so the law does not require a physician director there. Most multi-state clinics have one anyway, because the collaboration agreements in restricted states need a physician and because pharmacies and labs often want a named responsible physician.

Can the medical director be the collaborating physician for every NP? Only where each state's collaboration rules allow it, which usually means the physician is licensed in that state and within that state's ratio and review requirements. A national clinic usually needs collaborating physicians by state, coordinated by the director rather than replaced by one.

Can the director be paid in equity? Equity in the professional entity is ownership and is governed by the corporate practice rules of each state. Equity in the management company is possible in some structures but should be granted on terms unrelated to prescribing volume, valued independently, and reviewed by counsel in the states that enforce fee-splitting rules; it is the term most likely to turn a clean structure into a contested one.

What happens when the director leaves? The professional entity appoints a successor, the protocols stay with the entity, and the providers keep practising under them without interruption. If any of those three things is not true in the current structure, that is the gap to close first.